Dermorphin

High-potency μ-opioid-receptor research heptapeptide · strict controls required

Lot-specific released result; request raw chromatography, peptide content and orthogonal identity data · target, verify batch COACAS 77614-16-5RUO

Research statusResearch tool with historical literature; not approved for human or veterinary use reference context · supplied material is RUO

Supplied formLinear D-Ala-containing heptapeptide with C-terminal amide

Lead timeConfirmed with quote

Dermorphin — Lot-specific lyophilized solid; confirm colour and physical form on the released-batch COA

Dermorphin — Lot-specific lyophilized solid; confirm colour and physical form on the released-batch COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research relevance includes mu-opioid-receptor pharmacology, D-amino-acid peptide structure-activity relationships, analytical method development and anti-doping detection
Model-specific potency and analgesia findings are not product benefits or dosing guidance.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 77614-16-5
Formula: C₄₀H₅₀N₈O₁₀
Molecular weight: 802.9 g/mol
Appearance: Lot-specific lyophilized solid; confirm colour and physical form on the released-batch COA
Purity: Lot-specific released result; request raw chromatography, peptide content and orthogonal identity data · target, verify batch COA
Storage: Follow the released-lot COA and manufacturer stability instructions. Keep sealed and protected from moisture, heat and light; do not infer prepared-solution stability from powder specifications.
MOQ: On request
Lead time: Confirmed with quote

PubChem CID 5485199

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Dermorphin

Dermorphin is a D-Ala-containing heptapeptide first isolated from Phyllomedusa frog skin secretion and used as a high-affinity mu-opioid-receptor research tool. Its extreme experimental potency and misuse history require strict controls. Historical animal and intrathecal human research did not lead to an approved medicine. This material is not for human or veterinary use.

In-vitro opioid-receptor pharmacology, peptide structure-activity research, LC-MS/MS analytical method development, reference-standard work and anti-doping research
These are research applications, not clinical indications.

Mechanism context

The question the literature is testing

Dermorphin is a potent mu-opioid-receptor agonist peptide. The N-terminal Tyr-D-Ala-Phe-Gly motif is central to receptor activity, and D-Ala contributes proteolytic resistance relative to common endogenous opioid peptides. Results depend strongly on species, route, tissue and assay and should not be translated into human-use claims.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaOther research materials

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary use
Dermorphin is a high-potency μ-opioid-receptor agonist
The FEI 2025 Equine Prohibited Substances List records it as a banned peptide opioid-receptor agonist; sport-related buyers must verify the current governing list
Handle under the SDS, institutional controlled-material and chemical-hygiene rules, and verify local legal and import requirements
Chemical purity does not establish clinical safety or injectable suitability.

Interactions reported in the literature

Not applicable as patient or veterinary advice
Experimental antagonist or receptor-comparison designs must be defined and approved within the research protocol.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Dermorphin factory batch COAs

Dermorphin 2 mg Factory batch COA protected preview

Dermorphin2 mg · WHJLP-DP2-260602-A

Dermorphin 5 mg Factory batch COA protected preview

Dermorphin5 mg · WHJLP-DP5-260602-A

Dermorphin 10 mg Factory batch COA protected preview

Dermorphin10 mg · WHJLP-DP10-260602-A

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require exact sequence and stereochemistry, C-terminal amidation, free-base or salt assignment, intact mass, LC-MS identity, RP-HPLC purity with method, peptide content, counterion, water and residual solvents
Sterility and endotoxin are separate claims requiring released-lot tests.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

DERM-02MG2 mg10 vials

DERM-05MG5 mg10 vials

DERM-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA and manufacturer stability instructions. Keep sealed and protected from moisture, heat and light; do not infer prepared-solution stability from powder specifications.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: PubChem CIDs 5485199 and 131698721. Pharmacology and history: the original 1981 isolation work, the 1983 human prolactin study and the cited historical review. Analytical and anti-doping context: equine LC-MS/MS and pharmacokinetic studies plus the FEI 2025 list. Kambô reports concern complex frog secretion, not purified Dermorphin alone.

01
Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvagei
International Journal of Peptide and Protein Research · 1981 · peer-reviewed original research (landmark discovery paper)
Open source
02
Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin
British Journal of Pharmacology · 1981 · peer-reviewed original research (landmark pharmacology paper)
Open source
03
Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation
Journal of Pain Research · 2018 · peer-reviewed narrative review
Open source
04
Detection, quantification, and identification of dermorphin in equine plasma and urine by LC-MS/MS for doping control
Analytical and Bioanalytical Chemistry · 2013 · peer-reviewed original research (analytical/forensic toxicology)
Open source
05
Development of a comprehensive approach to quality control of dermorphin derivative -- representative of synthetic opioid peptides with non-narcotic type of analgesia
Scientia Pharmaceutica · 2025 · peer-reviewed original research (analytical chemistry / quality control)
Open source
06
The neurotropic activity of novel dermorphin analogs active at systemic and noninvasive administration
International Journal of Molecular Sciences · 2025 · peer-reviewed original research
Open source
07
Shamanic Kambo frog hyponatremic toxicity leading to brain death: a case report
Cureus · 2025 · peer-reviewed case report
Open source
08
Toxic hepatitis caused by the excretions of the Phyllomedusa bicolor frog -- a case report
Clinical and Experimental Hepatology · 2017 · peer-reviewed case report
Open source

Product FAQ

Questions buyers ask about Dermorphin

What identity information is essential for Dermorphin procurement?+

Confirm the seven-residue sequence, D-Ala stereochemistry, C-terminal amide, free-base or salt form, counterion and net peptide-content basis. PubChem records for free base and TFA-associated material have different formula and mass conventions. A product name, white powder or nominal HPLC percentage cannot establish the supplied chemical form.

What additional controls are appropriate for this high-potency material?+

Use the SDS, institutional controlled-material procedures, restricted access, documented inventory and applicable import or legal review. The FEI 2025 Equine Prohibited Substances List records Dermorphin as a banned peptide opioid-receptor agonist; buyers working in sport must verify the current governing list. That equine classification must not be represented as a WADA human-athlete listing or a universal scheduling decision.

Dermorphin

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Dermorphin

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Dermorphin factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvagei

Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin

Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation

Detection, quantification, and identification of dermorphin in equine plasma and urine by LC-MS/MS for doping control

Development of a comprehensive approach to quality control of dermorphin derivative -- representative of synthetic opioid peptides with non-narcotic type of analgesia

The neurotropic activity of novel dermorphin analogs active at systemic and noninvasive administration

Shamanic Kambo frog hyponatremic toxicity leading to brain death: a case report

Toxic hepatitis caused by the excretions of the Phyllomedusa bicolor frog -- a case report

Questions buyers ask about Dermorphin

Compare adjacent molecules and documentation needs.

VIP

DSIP

Semax

Lemon Bottle